<p>持有 <strong>Alector, Inc.</strong> (NASDAQ:ALEC) 股票的投資者會感到寬慰，因為在過去的三十天裏，股價反彈了 27%，但它需要繼續上漲，以修復近期對投資者投資組合造成的損害。然而，上個月對過去一年 76% 的股價下跌幾乎沒有改善。</p>
<p>儘管股價大幅上漲，但考慮到美國生物技術行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 9.3 倍，甚至超過 49 倍的市銷率也並不罕見，Alector 目前仍然可能被視為一個強有力的買入機會，其市銷率為 1.3 倍。然而，市銷率可能較低是有原因的，需要進一步調查以確定是否合理。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對 Alector 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731"/></p>
<p>NasdaqGS:ALEC 市銷率與行業比較 2025 年 5 月 5 日</p>
<h3>Alector 最近的表現如何？</h3>
<p>最近一段時間，Alector 的表現不佳，因為其收入增長速度慢於大多數其他公司。也許市場預計當前的收入增長乏力趨勢將持續，這使得市銷率受到壓制。如果是這樣，現有股東可能會對股價未來的走勢感到失望。</p>
<p>想知道分析師如何看待 Alector 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
<h2>收入預測是否與低市銷率相符？</h2>
<p>Alector 的市銷率對於一家預計將實現非常低增長甚至收入下降的公司來説是典型的，重要的是，其表現遠低於行業水平。</p>
<p>回顧過去一年，公司收入增長了 3.6%。然而，令人遺憾的是，收入從三年前的總額下降了 51%，這令人失望。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
<p>展望未來，預計未來三年將帶來減少的回報，七位分析師預計收入將每年下降 16%。與此同時，整個行業預計每年將擴張 157%，這描繪了一個不佳的前景。</p>
<p>根據這些信息，我們並不感到驚訝 Alector 的市銷率低於行業水平。然而，收入萎縮不太可能在長期內導致穩定的市銷率。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
<h2>我們可以從 Alector 的市銷率中學到什麼？</h2>
<p>即使在如此強勁的價格波動之後，Alector 的市銷率仍然落後於行業其他公司。通常，我們會警惕在做出投資決策時過於依賴市銷率，儘管它可以揭示市場其他參與者對公司的看法。</p>
<p>顯然，Alector 因其收入下滑的預期而維持低市銷率。由於行業內其他公司預計收入增長，Alector 的糟糕前景證明了其低市銷率。在這種情況下，很難看到股價在短期內強勁上漲。</p>
<p>還值得注意的是，我們發現了 <strong>Alector 的 3 個警告信號</strong>，您需要考慮這些因素。</p>
<p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>
<p>如果您打算交易 Alector，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
<p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
<p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
<p>贊助內容</p>

ALEC

<p>Alector, Inc.（納斯達克代碼：ALEC）在過去一個月的股價上漲了 27%，但在過去一年中股價下跌了 76%。儘管近期反彈，但該公司的市銷率（P/S）為 1.3 倍，仍然低於生物技術行業平均的 9.3 倍。Alector 的收入增長令人失望，預計在未來三年將每年下降 16%，與行業預期的 157% 的增長形成鮮明對比。這一疲軟的前景導致 Alector 的低市銷率，表明該股在未來的表現可能面臨挑戰</p>

<p>Those holding <strong>Alector, Inc.</strong> (NASDAQ:ALEC) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent damage it has caused to investor portfolios. But the last month did very little to improve the 76% share price decline over the last year.</p>
<div class="lb-trans"><p>持有 <strong>Alector, Inc.</strong> (NASDAQ:ALEC) 股票的投資者會感到寬慰，因為在過去的三十天裏，股價反彈了 27%，但它需要繼續上漲，以修復近期對投資者投資組合造成的損害。然而，上個月對過去一年 76% 的股價下跌幾乎沒有改善。</p>
</div><p>Although its price has surged higher, Alector may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 1.3x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 9.3x and even P/S higher than 49x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>儘管股價大幅上漲，但考慮到美國生物技術行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 9.3 倍，甚至超過 49 倍的市銷率也並不罕見，Alector 目前仍然可能被視為一個強有力的買入機會，其市銷率為 1.3 倍。然而，市銷率可能較低是有原因的，需要進一步調查以確定是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>Check out our latest analysis for Alector</p>
<div class="lb-trans"><p>查看我們對 Alector 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731" alt="" original-src="https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731"/></p>
<p>NasdaqGS:ALEC Price to Sales Ratio vs Industry May 5th 2025</p>
<div class="lb-trans"><p>NasdaqGS:ALEC 市銷率與行業比較 2025 年 5 月 5 日</p>
</div><h3>How Has Alector Performed Recently?</h3>
<div class="lb-trans"><h3>Alector 最近的表現如何？</h3>
</div><p>Recent times haven't been great for Alector as its revenue has been rising slower than most other companies. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>最近一段時間，Alector 的表現不佳，因為其收入增長速度慢於大多數其他公司。也許市場預計當前的收入增長乏力趨勢將持續，這使得市銷率受到壓制。如果是這樣，現有股東可能會對股價未來的走勢感到失望。</p>
</div><p>Keen to find out how analysts think Alector's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析師如何看待 Alector 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
</div><h2>Do Revenue Forecasts Match The Low P/S Ratio?</h2>
<div class="lb-trans"><h2>收入預測是否與低市銷率相符？</h2>
</div><p>Alector's P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry.</p>
<div class="lb-trans"><p>Alector 的市銷率對於一家預計將實現非常低增長甚至收入下降的公司來説是典型的，重要的是，其表現遠低於行業水平。</p>
</div><p>Retrospectively, the last year delivered a decent 3.6% gain to the company's revenues. Still, lamentably revenue has fallen 51% in aggregate from three years ago, which is disappointing. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顧過去一年，公司收入增長了 3.6%。然而，令人遺憾的是，收入從三年前的總額下降了 51%，這令人失望。因此，可以公平地説，最近的收入增長對公司來説並不理想。</p>
</div><p>Turning to the outlook, the next three years should bring diminished returns, with revenue decreasing 16% per annum as estimated by the seven analysts watching the company. Meanwhile, the broader industry is forecast to expand by 157% per year, which paints a poor picture.</p>
<div class="lb-trans"><p>展望未來，預計未來三年將帶來減少的回報，七位分析師預計收入將每年下降 16%。與此同時，整個行業預計每年將擴張 157%，這描繪了一個不佳的前景。</p>
</div><p>With this information, we are not surprised that Alector is trading at a P/S lower than the industry. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>根據這些信息，我們並不感到驚訝 Alector 的市銷率低於行業水平。然而，收入萎縮不太可能在長期內導致穩定的市銷率。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
</div><h2>What We Can Learn From Alector's P/S?</h2>
<div class="lb-trans"><h2>我們可以從 Alector 的市銷率中學到什麼？</h2>
</div><p>Even after such a strong price move, Alector's P/S still trails the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>即使在如此強勁的價格波動之後，Alector 的市銷率仍然落後於行業其他公司。通常，我們會警惕在做出投資決策時過於依賴市銷率，儘管它可以揭示市場其他參與者對公司的看法。</p>
</div><p>It's clear to see that Alector maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, Alector's poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>顯然，Alector 因其收入下滑的預期而維持低市銷率。由於行業內其他公司預計收入增長，Alector 的糟糕前景證明了其低市銷率。在這種情況下，很難看到股價在短期內強勁上漲。</p>
</div><p>It is also worth noting that we have found <strong>3 warning signs for Alector</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>還值得注意的是，我們發現了 <strong>Alector 的 3 個警告信號</strong>，您需要考慮這些因素。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>
</div><p>If you're looking to trade Alector, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您打算交易 Alector，請在專業人士信賴的最低成本平台 Interactive Brokers 開設賬户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多個國家和地區擁有客户，並可訪問 160 個市場，讓您可以通過一個集成賬户交易股票、期權、期貨、外匯、債券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受無隱藏費用、無賬户最低限額，外匯轉換率低至 0.03%，遠低於大多數經紀商提供的費用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>贊助內容</p>
</div>

Alector, Inc. (NASDAQ:ALEC) 的股票上漲了 27%，儘管其股價和業務表現仍然落後於行業水平